Cargando…

Outcomes and Prognostic Factors for Locally Recurrent Rectal Cancer Treated With Proton Beam Therapy

PURPOSE: Our objective was to report the outcome and prognostic factors for patients with locally recurrent rectal cancer (LRRC) treated with proton beam therapy (PBT) at our institution. METHODS AND MATERIALS: The study included PBT-treated patients with LRRC between December 2008 and December 2019...

Descripción completa

Detalles Bibliográficos
Autores principales: Takagawa, Yoshiaki, Suzuki, Motohisa, Yamaguchi, Hisashi, Seto, Ichiro, Azami, Yusuke, Machida, Masanori, Takayama, Kanako, Tominaga, Takuya, Murakami, Masao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991532/
https://www.ncbi.nlm.nih.gov/pubmed/36896217
http://dx.doi.org/10.1016/j.adro.2023.101192
_version_ 1784902171180924928
author Takagawa, Yoshiaki
Suzuki, Motohisa
Yamaguchi, Hisashi
Seto, Ichiro
Azami, Yusuke
Machida, Masanori
Takayama, Kanako
Tominaga, Takuya
Murakami, Masao
author_facet Takagawa, Yoshiaki
Suzuki, Motohisa
Yamaguchi, Hisashi
Seto, Ichiro
Azami, Yusuke
Machida, Masanori
Takayama, Kanako
Tominaga, Takuya
Murakami, Masao
author_sort Takagawa, Yoshiaki
collection PubMed
description PURPOSE: Our objective was to report the outcome and prognostic factors for patients with locally recurrent rectal cancer (LRRC) treated with proton beam therapy (PBT) at our institution. METHODS AND MATERIALS: The study included PBT-treated patients with LRRC between December 2008 and December 2019. Treatment response was stratified using an initial imaging test after PBT. Overall survival (OS), progression-free survival (PFS), and local control (LC) were estimated using the Kaplan-Meier method. Each outcome's prognostic factors were verified using the Cox proportional hazards model. RESULTS: Twenty-three patients were enrolled (median follow-up, 37.4 months). There were 11 patients with complete response (CR) or complete metabolic response (CMR), 8 with partial response or partial metabolic response, 2 with stable disease or stable metabolic response, and 2 with progressive disease or progressive metabolic disease. Three- and 5-year OS, PFS, and LC were 72.1% and 44.6%, 37.9% and 37.9%, and 55.0% and 47.2%, respectively, with 54.4 months’ median survival time. The maximum standardized uptake value of fluorine-18-fluorodeoxyglucose-positron emission tomography–computed tomography ((18)F-FDG-PET/CT) before PBT (cutoff value, 10) showed significant differences in OS (P = .03), PFS (P = .027), and LC (P = .012). The patients who achieved CR or CMR after PBT had significantly better LC than those with non-CR or non-CMR (hazard ratio, 4.49; 95% confidence interval, 1.14-17.63; P = .021). Older patients (aged ≥65 years) had significantly higher LC and PFS rates. Patients with pain before PBT and larger tumors (≥30 mm) also had significantly lower PFS. Of 23 patients, 12 (52%) experienced further local recurrence after PBT. One patient developed grade 2 acute radiation dermatitis. Regarding late toxicity, grade 4 late gastrointestinal toxic effects were recorded in 3 patients, in 2 of whom reirradiation was associated with further local recurrence after PBT. CONCLUSIONS: The results showed that PBT may have potential to be a good treatment option for LRRC. (18)F-FDG-PET/CT before and after PBT may be useful for assessing tumor response and predicting outcomes.
format Online
Article
Text
id pubmed-9991532
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-99915322023-03-08 Outcomes and Prognostic Factors for Locally Recurrent Rectal Cancer Treated With Proton Beam Therapy Takagawa, Yoshiaki Suzuki, Motohisa Yamaguchi, Hisashi Seto, Ichiro Azami, Yusuke Machida, Masanori Takayama, Kanako Tominaga, Takuya Murakami, Masao Adv Radiat Oncol Scientific Article PURPOSE: Our objective was to report the outcome and prognostic factors for patients with locally recurrent rectal cancer (LRRC) treated with proton beam therapy (PBT) at our institution. METHODS AND MATERIALS: The study included PBT-treated patients with LRRC between December 2008 and December 2019. Treatment response was stratified using an initial imaging test after PBT. Overall survival (OS), progression-free survival (PFS), and local control (LC) were estimated using the Kaplan-Meier method. Each outcome's prognostic factors were verified using the Cox proportional hazards model. RESULTS: Twenty-three patients were enrolled (median follow-up, 37.4 months). There were 11 patients with complete response (CR) or complete metabolic response (CMR), 8 with partial response or partial metabolic response, 2 with stable disease or stable metabolic response, and 2 with progressive disease or progressive metabolic disease. Three- and 5-year OS, PFS, and LC were 72.1% and 44.6%, 37.9% and 37.9%, and 55.0% and 47.2%, respectively, with 54.4 months’ median survival time. The maximum standardized uptake value of fluorine-18-fluorodeoxyglucose-positron emission tomography–computed tomography ((18)F-FDG-PET/CT) before PBT (cutoff value, 10) showed significant differences in OS (P = .03), PFS (P = .027), and LC (P = .012). The patients who achieved CR or CMR after PBT had significantly better LC than those with non-CR or non-CMR (hazard ratio, 4.49; 95% confidence interval, 1.14-17.63; P = .021). Older patients (aged ≥65 years) had significantly higher LC and PFS rates. Patients with pain before PBT and larger tumors (≥30 mm) also had significantly lower PFS. Of 23 patients, 12 (52%) experienced further local recurrence after PBT. One patient developed grade 2 acute radiation dermatitis. Regarding late toxicity, grade 4 late gastrointestinal toxic effects were recorded in 3 patients, in 2 of whom reirradiation was associated with further local recurrence after PBT. CONCLUSIONS: The results showed that PBT may have potential to be a good treatment option for LRRC. (18)F-FDG-PET/CT before and after PBT may be useful for assessing tumor response and predicting outcomes. Elsevier 2023-02-06 /pmc/articles/PMC9991532/ /pubmed/36896217 http://dx.doi.org/10.1016/j.adro.2023.101192 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Scientific Article
Takagawa, Yoshiaki
Suzuki, Motohisa
Yamaguchi, Hisashi
Seto, Ichiro
Azami, Yusuke
Machida, Masanori
Takayama, Kanako
Tominaga, Takuya
Murakami, Masao
Outcomes and Prognostic Factors for Locally Recurrent Rectal Cancer Treated With Proton Beam Therapy
title Outcomes and Prognostic Factors for Locally Recurrent Rectal Cancer Treated With Proton Beam Therapy
title_full Outcomes and Prognostic Factors for Locally Recurrent Rectal Cancer Treated With Proton Beam Therapy
title_fullStr Outcomes and Prognostic Factors for Locally Recurrent Rectal Cancer Treated With Proton Beam Therapy
title_full_unstemmed Outcomes and Prognostic Factors for Locally Recurrent Rectal Cancer Treated With Proton Beam Therapy
title_short Outcomes and Prognostic Factors for Locally Recurrent Rectal Cancer Treated With Proton Beam Therapy
title_sort outcomes and prognostic factors for locally recurrent rectal cancer treated with proton beam therapy
topic Scientific Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991532/
https://www.ncbi.nlm.nih.gov/pubmed/36896217
http://dx.doi.org/10.1016/j.adro.2023.101192
work_keys_str_mv AT takagawayoshiaki outcomesandprognosticfactorsforlocallyrecurrentrectalcancertreatedwithprotonbeamtherapy
AT suzukimotohisa outcomesandprognosticfactorsforlocallyrecurrentrectalcancertreatedwithprotonbeamtherapy
AT yamaguchihisashi outcomesandprognosticfactorsforlocallyrecurrentrectalcancertreatedwithprotonbeamtherapy
AT setoichiro outcomesandprognosticfactorsforlocallyrecurrentrectalcancertreatedwithprotonbeamtherapy
AT azamiyusuke outcomesandprognosticfactorsforlocallyrecurrentrectalcancertreatedwithprotonbeamtherapy
AT machidamasanori outcomesandprognosticfactorsforlocallyrecurrentrectalcancertreatedwithprotonbeamtherapy
AT takayamakanako outcomesandprognosticfactorsforlocallyrecurrentrectalcancertreatedwithprotonbeamtherapy
AT tominagatakuya outcomesandprognosticfactorsforlocallyrecurrentrectalcancertreatedwithprotonbeamtherapy
AT murakamimasao outcomesandprognosticfactorsforlocallyrecurrentrectalcancertreatedwithprotonbeamtherapy